Why Immunic, Inc.’s (IMUX) Stock Is Up 5.33%
As of Thursday, October 15, Immunic, Inc.’s IMUX share price has surged by 5.33%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Commentary & Analysis
Why Immunic, Inc.’s (IMUX) Stock Is Down 5.91%
As of Tuesday, October 13, Immunic, Inc.’s IMUX share price has dipped by 5.91%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Immunic, Inc.’s (IMUX) Stock Is Up 7.01%
As of Friday, October 09, Immunic, Inc.’s IMUX share price has surged by 7.01%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Immunic, Inc.’s (IMUX) Stock Is Up 12.17%
As of Friday, October 09, Immunic, Inc.’s IMUX share price has surged by 12.17%, which has investors questioning if this is right time to sell.Omar Beirat
Why Immunic, Inc.’s (IMUX) Stock Is Down 6.02%
As of Friday, October 02, Immunic, Inc.’s IMUX share price has dipped by 6.02%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | IMUX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $95.1 | $208.8 | 22% |
|
| Shares Out (Mil) | 42.5 | 53.9 | 44% |
|
| Institutional Ownership | 98.2% | 93.1% | 77% |
|
| Float (Mil) | 12.0 | 41.4 | 22% |
|
| Beta | 1.40 | 0.95 | 79% |
|
| Avg Daily Volume (000s) | 414 | 614 | 55% |
|
| Price Change (52-week) |
(16.8%) | 45.3% | 39% |
|
| Growth | IMUX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (17.2%) | (10.2%) | 23% |
|
| EPS (5yr) | 26.0% | 15.7% | 77 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.7%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 10 | |
| Current EPS | ($0.962) | ($3.568) | ($2.427) | |
| Month Ago EPS | ($0.962) | ($3.568) | ($2.427) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($1.193) | ($4.383) | ($3.546) | |
| Year/Year Chg | 20.0% | (42.8%) | (59.5%) | |
| Financials | IMUX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($112) | ($44) | 10% |
|
| EPS (TTM) | ($3.998) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($88) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $100 | $2 | 77% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 13% |
|
| Enterprise Value (Q1) (Mil) | $70 | $174 | 18% |
|
| Valuation | IMUX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.75 | 2.09 | 17% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IMUX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (101.1%) | (47.2%) | 5% |
|
| ROE | (138.2%) | (54.2%) | 7% |
|
| Liabilities to Assets | 19.8% | 29.1% | 13% |
|
| F-Score | 3 | 2 | 18% |
|
Immunic, Inc. did not pass any screens on 10/16/2026.
